Study ID,Study,Experiment Name,Experiment Notes,Strain Ont ID,Strain,Sex,Age,# of Animals,Sample Notes,Clinical Measurement Ont ID,Phenotype,Formula,Clinical Measurement Notes,Average Type,Value,Units,SEM,SD,Method Ont ID,Method,Method Site,Method Duration,Method Notes,Post Insult Type,Post Insult Time Value,Post Insult Time Unit,Conditions,Record ID,Condition 1a,Condition 1b,Condition 2a,Condition 2b 1159,"Vingsbo C, et al., Am J Pathol 1996 Nov;149(5):1675-83",joint integrity trait,,RS:0000513,LEW/Han,both,98 days to 56 days,11,,CMO:0001456,percentage of study population developing chronic experimental arthritis during a period of time,,,,82,%,,,MMO:0000163,in vivo visual assessment,,0.0,,,,,pristane (150 ul) ,69676,pristane (150 ul) ,,, 1159,"Vingsbo C, et al., Am J Pathol 1996 Nov;149(5):1675-83",joint integrity trait,,RS:0000497,LEW.1F,both,98 days to 56 days,10,,CMO:0001456,percentage of study population developing chronic experimental arthritis during a period of time,,,,100,%,,,MMO:0000163,in vivo visual assessment,,0.0,,,,,pristane (150 ul) ,69677,pristane (150 ul) ,,, 1159,"Vingsbo C, et al., Am J Pathol 1996 Nov;149(5):1675-83",joint integrity trait,,RS:0002062,LEW.1N,both,98 days to 56 days,11,,CMO:0001456,percentage of study population developing chronic experimental arthritis during a period of time,,,,54,%,,,MMO:0000163,in vivo visual assessment,,0.0,,,,,pristane (150 ul) ,69678,pristane (150 ul) ,,, 1159,"Vingsbo C, et al., Am J Pathol 1996 Nov;149(5):1675-83",joint integrity trait,,RS:0001675,DA/ZtmRhd,both,98 days to 56 days,17,,CMO:0001456,percentage of study population developing chronic experimental arthritis during a period of time,,,,100,%,,,MMO:0000163,in vivo visual assessment,,0.0,,,,,pristane (150 ul) ,69679,pristane (150 ul) ,,, 1159,"Vingsbo C, et al., Am J Pathol 1996 Nov;149(5):1675-83",joint integrity trait,,RS:0000208,E3/ZtmRhd,both,98 days to 56 days,23,,CMO:0001456,percentage of study population developing chronic experimental arthritis during a period of time,,,,0,%,,,MMO:0000163,in vivo visual assessment,,0.0,,,,,pristane (150 ul) ,69680,pristane (150 ul) ,,, 1159,"Vingsbo C, et al., Am J Pathol 1996 Nov;149(5):1675-83",joint integrity trait,,RS:0000383,DXE2/Ztm,both,98 days to 56 days,24,,CMO:0001456,percentage of study population developing chronic experimental arthritis during a period of time,,,,30,%,,,MMO:0000163,in vivo visual assessment,,0.0,,,,,pristane (150 ul) ,69682,pristane (150 ul) ,,, 1159,"Vingsbo C, et al., Am J Pathol 1996 Nov;149(5):1675-83",joint integrity trait,,RS:0000384,DXE3/Ztm,both,98 days to 56 days,20,,CMO:0001456,percentage of study population developing chronic experimental arthritis during a period of time,,,,0,%,,,MMO:0000163,in vivo visual assessment,,0.0,,,,,pristane (150 ul) ,69683,pristane (150 ul) ,,, 1160,"Vingsbo-Lundberg C, et al., Nat Genet 1998 Dec;20(4):401-4",joint integrity trait,,RS:0001675,DA/ZtmRhd,both,0 days,30,,CMO:0001456,percentage of study population developing chronic experimental arthritis during a period of time,,,,87,%,,,MMO:0000163,in vivo visual assessment,,1.0368E7,,,,,pristane (150 ul) (for 120 days),69595,pristane (150 ul) (for 120 days),,, 1160,"Vingsbo-Lundberg C, et al., Nat Genet 1998 Dec;20(4):401-4",joint integrity trait,,RS:0000208,E3/ZtmRhd,both,0 days,25,,CMO:0001456,percentage of study population developing chronic experimental arthritis during a period of time,,,,0,%,,,MMO:0000163,in vivo visual assessment,,1.0368E7,,,,,pristane (150 ul) (for 120 days),69966,pristane (150 ul) (for 120 days),,, 1241,"Furuya T, et al., Hum Mol Genet 2000 Sep 22;9(15):2241-50",joint integrity trait,,RS:0000073,BBDR/Rhw,male,126 days to 66 days,11,,CMO:0001456,percentage of study population developing chronic experimental arthritis during a period of time,,,,100,%,,,MMO:0000163,in vivo visual assessment,,0.0,,,,,Freund's incomplete adjuvant (50 %) (between 1 and 7 days) and type II collagen (2 mg/kg) (between 1 and 7 days) then Freund's incomplete adjuvant (50 %) (between 1 and 35 days) and type II collagen (100 ug) (between 1 and 35 days),69921,Freund's incomplete adjuvant (50 %) (between 1 and 7 days),type II collagen (2 mg/kg) (between 1 and 7 days),Freund's incomplete adjuvant (50 %) (between 1 and 35 days),type II collagen (100 ug) (between 1 and 35 days) 1241,"Furuya T, et al., Hum Mol Genet 2000 Sep 22;9(15):2241-50",joint integrity trait,,RS:0000073,BBDR/Rhw,female,126 days to 66 days,13,,CMO:0001456,percentage of study population developing chronic experimental arthritis during a period of time,,,,100,%,,,MMO:0000163,in vivo visual assessment,,0.0,,,,,Freund's incomplete adjuvant (50 %) (between 1 and 7 days) and type II collagen (2 mg/kg) (between 1 and 7 days) then Freund's incomplete adjuvant (50 %) (between 1 and 35 days) and type II collagen (100 ug) (between 1 and 35 days),69922,Freund's incomplete adjuvant (50 %) (between 1 and 7 days),type II collagen (2 mg/kg) (between 1 and 7 days),Freund's incomplete adjuvant (50 %) (between 1 and 35 days),type II collagen (100 ug) (between 1 and 35 days) 1241,"Furuya T, et al., Hum Mol Genet 2000 Sep 22;9(15):2241-50",joint integrity trait,,RS:0000154,BN/SsN,male,126 days to 66 days,13,,CMO:0001456,percentage of study population developing chronic experimental arthritis during a period of time,,,,0,%,,,MMO:0000163,in vivo visual assessment,,0.0,,,,,Freund's incomplete adjuvant (50 %) (between 1 and 7 days) and type II collagen (2 mg/kg) (between 1 and 7 days) then Freund's incomplete adjuvant (50 %) (between 1 and 35 days) and type II collagen (100 ug) (between 1 and 35 days),69923,Freund's incomplete adjuvant (50 %) (between 1 and 7 days),type II collagen (2 mg/kg) (between 1 and 7 days),Freund's incomplete adjuvant (50 %) (between 1 and 35 days),type II collagen (100 ug) (between 1 and 35 days) 1241,"Furuya T, et al., Hum Mol Genet 2000 Sep 22;9(15):2241-50",joint integrity trait,,RS:0000154,BN/SsN,female,126 days to 66 days,7,,CMO:0001456,percentage of study population developing chronic experimental arthritis during a period of time,,,,0,%,,,MMO:0000163,in vivo visual assessment,,0.0,,,,,Freund's incomplete adjuvant (50 %) (between 1 and 7 days) and type II collagen (2 mg/kg) (between 1 and 7 days) then Freund's incomplete adjuvant (50 %) (between 1 and 35 days) and type II collagen (100 ug) (between 1 and 35 days),69924,Freund's incomplete adjuvant (50 %) (between 1 and 7 days),type II collagen (2 mg/kg) (between 1 and 7 days),Freund's incomplete adjuvant (50 %) (between 1 and 35 days),type II collagen (100 ug) (between 1 and 35 days)